Market Snapshot

BSE Sensex: 77053.91 0.51%
BSE 500: 35604.92 0.72%
BSE 200: 11143.73 0.63%
BSE 100: 25446.9 0.58%
BSE BANKEX: 63327.17 0.22%
BSE IT: 28066.82 1.51%
Nifty 50: 24007.2 0.46%
Nifty 500: 22711.25 0.63%
Nifty 200: 13733.85 0.56%
Nifty 100: 24946.55 0.48%
Nifty Midcap 100: 59916.65 0.91%
Nifty Small 100: 17782 1.22%
Nifty IT: 28906.35 1.32%
Nifty PSU Bank: 8856.7 0.52%

News:

Innovision secures labour supp...
IDFC FIRST Bank Q4 PAT rises 4...
Supreme Petrochem Q4 PAT jumps...
RBL Bank Q4 PAT spurts 234% Yo...
Lodha Developers Q4 PAT jumps ...

Lincoln Pharmaceuticals Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

Invest

27 Apr 2026 | 09:39 AM

606.60

1.05 (0.17%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Outperforms Index

2.26%

Return (1Y)

Beaten Nifty 50 by 2.9%
More Volatile

2.33%

Standard Deviation (1Y)

Higher than Nifty 50 by 1.48%
Not so consistent

4/12

Months

underperformed Nifty 50
AxisDirect View

No View

52 Week High-Low

677

440

News & Announcements

Lincoln Pharmaceuticals consolidated net profit rises 37.70% in the December 2025 quarter
74 days ago

Lincoln Pharmaceuticals consolidated net profit rises 37.70% in the December 2025 quarter

12 - Feb - 2026 12:00 | 74 days ago

Net profit of Lincoln Pharmaceuticals rose 37.70% to Rs 28.60 crore in the quarter ended December 2025 as against Rs 20.77 crore during the previous quarter ended December 2024. Sales rose 13.49% to Rs 166.32 crore in the quarter ended December 2025 as against Rs 146.55 crore during the previous quarter ended December 2024.

Particulars Quarter Ended
Dec. 2025 Dec. 2024 % Var.

Sales 166.32 146.55 13

OPM % 14.18 16.14 -

PBDT 38.44 31.91 20

PBT 34.72 28.68 21

NP 28.60 20.77 38

Powered by Capital Market - Live News
Lincoln Pharmaceuticals to hold board meeting
81 days ago

Lincoln Pharmaceuticals to hold board meeting

05 - Feb - 2026 12:00 | 81 days ago

Lincoln Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 February 2026.
Powered by Capital Market - Live News
Lincoln Pharmaceuticals consolidated net profit declines 24.12% in the September 2025 quarter
165 days ago

Lincoln Pharmaceuticals consolidated net profit declines 24.12% in the September 2025 quarter

13 - Nov - 2025 12:00 | 165 days ago

Net profit of Lincoln Pharmaceuticals declined 24.12% to Rs 19.98 crore in the quarter ended September 2025 as against Rs 26.33 crore during the previous quarter ended September 2024. Sales rose 1.33% to Rs 163.36 crore in the quarter ended September 2025 as against Rs 161.21 crore during the previous quarter ended September 2024.

Particulars Quarter Ended
Sep. 2025 Sep. 2024 % Var.

Sales 163.36 161.21 1

OPM % 15.57 17.60 -

PBDT 32.43 38.01 -15

PBT 28.81 34.78 -17

NP 19.98 26.33 -24

Powered by Capital Market - Live News
Lincoln Pharmaceuticals declines after weak Q2 performance
165 days ago

Lincoln Pharmaceuticals declines after weak Q2 performance

13 - Nov - 2025 12:00 | 165 days ago

EBITDA fell by 14.86% to Rs 32.66 crore in Q2 FY26 from Rs 38.35 crore in Q2 FY25.
Profit before tax in Q2 FY26 stood at Rs 28.81 crore, down by 17.17% from Rs 34.78 crore recorded in Q2 FY25.
Lincoln Pharmaceuticals stated that the company is targeting a revenue of Rs 1,000 crore within the next three years, driven by business expansion into high-value product lines and entry into new markets. This goal is part of a broader strategy to achieve a 15-18% annual growth rate, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments.
Mahendra Patel, managing director, Lincoln Pharmaceuticals, said: We are pleased to report another strong quarter, reflecting our continued focus on sustainable growth and value creation.
Our growth momentum is supported by expansion into high-value therapeutic segments such as cardiac, diabetic, dermatology, and ENT, along with new product introductions and entry into emerging markets.
The commissioning of our Bulk Drug Manufacturing Plant and progress at our Cephalosporin facility further strengthen our backward integration and export capabilities.
With a debt-free balance sheet, we are well positioned to deliver sustainable, profitable growth and enhance long-term shareholder value.
Lincoln Pharmaceuticals has been manufacturing pharmaceutical formulations in the domestic market as well as exporting formulations. The company is part of the Lincoln Group, which manufactures pharmaceuticals formulations in categories such as generics, anti-malarial, anti-diabetic, gynaecology products, vitamins, minerals and anti-oxidants.

Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

FII shareholding in Lincoln Pharmaceuticals Ltd has increased by 10.65% since past 3 Months
MF shareholding in Lincoln Pharmaceuticals Ltd has increased by 5% since past 3 Months
FII shareholding in Lincoln Pharmaceuticals Ltd has increased by 3.99% since past 1 Year
MF shareholding in Lincoln Pharmaceuticals Ltd has increased by 23.53% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Dec. 2025	Dec. 2024	% Var.
Sales	166.32	146.55	13
OPM %	14.18	16.14	-
PBDT	38.44	31.91	20
PBT	34.72	28.68	21
NP	28.60	20.77	38

Particulars	Quarter Ended
	Sep. 2025	Sep. 2024	% Var.
Sales	163.36	161.21	1
OPM %	15.57	17.60	-
PBDT	32.43	38.01	-15
PBT	28.81	34.78	-17
NP	19.98	26.33	-24

General Notifications

My Notifications

Research Notifications

Lincoln Pharmaceuticals Ltd Share Price – NSE / BSE Pharmaceuticals, Small Cap

606.60 1.05 (0.17%)

News & Announcements

Price vs Volume

Stock Trivia

Lincoln Pharmaceuticals Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap

606.60

1.05 (0.17%)